Mexico: Compulsory licences and non-working

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mexico: Compulsory licences and non-working

In recent times we became aware of some requests for advice as to whether a statement of excuse for the non-working of a patented invention in Mexico should be filed with the Patent Office (IMPI).

It is true that the Mexican IP Law establishes that in the case of patented inventions, after three years from the date of grant of the patent, or four years of the filing of the application, whichever occurs later, any person may request IMPI to grant a compulsory licence to exploit the invention, when the invention is not worked in Mexico, unless there are justified reasons.

Notwithstanding this, there is no express obligation or a requirement to file evidence of working the patent or proofs of arguments related to the excuses for non-working the claimed invention to keep the patent/application alive or enforceable. In this regard, a recommendation to provide a statement or periodically file proofs of working, stating that they would prevent the filing or grant of a compulsory licence is completely unsupported.

According to the law, if a third party files an application for a compulsory licence, the title holder would have one year from the date IMPI informs about the request for compulsory licence to cure the non-exploitation of the invention and start working the patent in Mexico, either by exporting the patented product or using it in our country directly or through a licence recorded before IMPI. Therefore, the risk of a compulsory licence may not be actually reduced by filing a statement of working the patent.

In the case of a petition for a compulsory licence, the applicant also has the obligation to provide evidence showing technical and economic capacity for work the patent in Mexico. Furthermore, the IP Law establishes that after giving the opportunity to cure the non-exploitation there should be a hearing with the parties in which IMPI will decide on the grant of a compulsory licence, and if IMPI decides to grant it, it will set forth its duration, conditions, field of application and amount of royalties which should be fair and reasonable.

In Mexico the IP law does not define nor provide examples or parameters for justified excuse for not working a patent, nor how it would be proved or argued, therefore any kind of evidence allowed by the local regulations should be accepted by IMPI to sustain the justified excuse for not working the patent as an exception for the potential compulsory licence proceeding and eventually analysed by this authority on a case-by-case basis.

We have not been aware that a compulsory licence has been granted in recent years in Mexico; however if it occurs it would be subject to further and detailed study.

Alejandro Torres


OlivaresPedro Luis Ogazón No 17Col San Angel01000 México DFTel: +5255 53 22 30 00Fax: +5255 53 22 30 01olivlaw@olivares.com.mxwww.olivares.com.mx

more from across site and SHARED ros bottom lb

More from across our site

VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Gift this article